Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 2
2005 2
2006 2
2007 2
2008 2
2011 1
2012 1
2013 5
2015 1
2016 1
2018 1
2019 2
2020 2
2021 1
2022 5
2023 7
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Results by year

Filters applied: . Clear all
Page 1
[Immunotherapy in non-small cell lung cancer patients: back to the future.].
Roberto M, Botticelli A, Cecere F, Cognetti F, Giusti R, Gelibter A, Lugini A, Nelli F, Nuti M, Santini D, Marchetti P. Roberto M, et al. Among authors: nelli f. Recenti Prog Med. 2019 Dec;110(12):587-593. doi: 10.1701/3278.32517. Recenti Prog Med. 2019. PMID: 31909761 Review. Italian.
Immune-related adverse events and disease outcomes after the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients receiving immune checkpoint inhibitors.
Nelli F, Giannarelli D, Fabbri A, Virtuoso A, Giron Berrios JR, Marrucci E, Fiore C, Schirripa M, Signorelli C, Chilelli MG, Primi F, Panichi V, Topini G, Silvestri MA, Ruggeri EM. Nelli F, et al. Cancer Immunol Immunother. 2023 Oct;72(10):3217-3228. doi: 10.1007/s00262-023-03489-1. Epub 2023 Jul 10. Cancer Immunol Immunother. 2023. PMID: 37428196
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study.
Fabbri A, Nelli F, Botticelli A, Giannarelli D, Marrucci E, Fiore C, Virtuoso A, Scagnoli S, Pisegna S, Alesini D, Sini V, Orlandi A, Fabi A, Piacentini F, Moscetti L, D'Auria G, Gamucci T, Mazzotta M, Pizzuti L, Vici P, Cretella E, Scavina P, La Cesa A, Persano M, Atzori F, Ruggeri EM. Fabbri A, et al. Among authors: nelli f. Front Oncol. 2023 Jun 27;13:1177681. doi: 10.3389/fonc.2023.1177681. eCollection 2023. Front Oncol. 2023. PMID: 37441419 Free PMC article.
Immune-related Thyroid Dysfunction (irTD) in Non-small Cell Lung Cancer (NSCLC) Correlates With Response and Survival.
Chilelli MG, Signorelli C, Giron Berrios JR, Onorato A, Nelli F, Fabbri MA, Primi F, Marrucci E, Virtuoso A, Schirripa M, Mazzotta M, Ruggeri EM. Chilelli MG, et al. Among authors: nelli f. Cancer Diagn Progn. 2022 Jan 3;2(1):55-63. doi: 10.21873/cdp.10076. eCollection 2022 Jan-Feb. Cancer Diagn Progn. 2022. PMID: 35400002 Free PMC article.
[Management of small cell lung cancer patient in the regions of Lazio, Umbria and Sardinia.].
Minuti G, Stefani A, Carpano S, D'Argento E, Giusti R, Martelli O, Metro G, Gelibter AJ, Antonini Cappellini GC, Carta A, Fadda GM, Nelli F, Ricciardi S, Russano M, Bria E, Cappuzzo F. Minuti G, et al. Among authors: nelli f. Recenti Prog Med. 2021 Oct;112(10):639-646. doi: 10.1701/3679.36653. Recenti Prog Med. 2021. PMID: 34647533 Italian.
[Management of the patient with extensive stage microcytoma. The importance of collaboration between oncology and radiotherapy.].
Minuti G, Stefani A, Trodella L, Antonini Cappellini G, Cecere F, Dionisi F, Di Salvatore M, Mariotti S, Mazzarella C, Nelli F, Pisegna S, Ricciardi S, Russano M, Ramella S, Bria E, Cappuzzo F. Minuti G, et al. Among authors: nelli f. Recenti Prog Med. 2023 Jul-Aug;114(7):414-425. doi: 10.1701/4062.40460. Recenti Prog Med. 2023. PMID: 37392104 Italian.
Dynamic Changes of Peripheral NK Cells Predict Outcome in Patients with PD-L1 Positive Non-small-cell Lung Cancer Undergoing Immune Checkpoint Inhibitors as Second-line Therapy.
Nelli F, Panichi V, Fabbri A, Natoni F, Giannarelli D, Topini G, Virtuoso A, Giron Berrios JR, Marrucci E, Pessina G, Silvestri MA, Ruggeri EM. Nelli F, et al. Cancer Invest. 2022 Sep;40(8):710-721. doi: 10.1080/07357907.2022.2092635. Epub 2022 Jun 26. Cancer Invest. 2022. PMID: 35736808
Rhabdomyolysis from erlotinib: a case report.
Moscetti L, Nelli F, Ruggeri EM. Moscetti L, et al. Among authors: nelli f. Tumori. 2011 May-Jun;97(3):415-6. doi: 10.1177/030089161109700327. Tumori. 2011. PMID: 21789026 No abstract available.
Dynamic changes in peripheral lymphocytes and antibody response following a third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in cancer patients.
Ruggeri EM, Nelli F, Giannarelli D, Fabbri A, Giron Berrios JR, Virtuoso A, Marrucci E, Mazzotta M, Schirripa M, Signorelli C, Chilelli MG, Primi F, Fiore C, Panichi V, Topini G, Silvestri MA. Ruggeri EM, et al. Among authors: nelli f. Sci Rep. 2022 Dec 19;12(1):21908. doi: 10.1038/s41598-022-25558-8. Sci Rep. 2022. PMID: 36535985 Free PMC article.
44 results